Investigators assessed outcomes following a radiotherapy dose of 4 Gy in 2 fractions vs 24 Gy in 12 fractions in patients with follicular lymphoma or marginal zone lymphoma.
Investigators of a phase 3 trial will compare epcoritamab with investigator’s choice of chemotherapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Loxo Oncology is preparing to initiate the global, randomized, BRUIN MCL-321 superiority study in patients with Bruton tyrosine kinase inhibitor-naïve disease.
Although rituximab is well-tolerated by children, infections are common and time to recovery of B lymphocytes, prolonged.
A team of investigators conducted a meta-analysis to assess outcomes following Helicobacter pylori eradication therapy as first-line treatment for patients with H pylori-negative gastric MALT lymphoma.
Although the risk for breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) has been well-documented, patients considering breast implants continue to be inadequately informed of the propensity for disease development.
Breyanzi is a CD19-directed genetically modified autologous T cell immunotherapy.
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
Investigators compared rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-miniCHOP) with R-miniCHOP plus lenalidomide in patients with diffuse large B-cell lymphoma (DLBCL) aged 80 years and older.
As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
The approval was based on data from an open-label phase 1/2 trial in patients aged 1 to 21 years that included 26 patients with relapsed or refractory, systemic ALK-positive ALCL after at least 1 systemic treatment.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
The biosimilar has been approved for the treatment of Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Granulomatosis with Polyangiitis, and Microscopic Polyangiitis.
Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).
Axi-cel demonstrated significant clinical benefit as a first-line treatment for patients with high-risk large B-cell lymphoma.
The bispecific CAR-T therapy targets CD20 and CD19.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Encouraging antitumor activity and durable responses were reported with odronextamab among patients with highly refractory B-cell NHLs.